Vitamin K: K1 Phylloquinone, K2 MK-4 & MK-7, Osteocalcin & the Calcium-Directing Vitamin

Clinical Definition & Overview

Vitamin K: K1 Phylloquinone, K2 MK-4 & MK-7, Osteocalcin & the Calcium-Directing Vitamin is a critical clinical pathway within Vitamin K under the Nutrient Database domain. In clinical practice, managing this area requires a structured, multi-disciplinary approach to optimize patient outcomes, mitigate secondary risks, and support baseline organ function. This protocol outlines the diagnostic markers, therapeutic targets, and evidence-graded lifestyle interventions necessary to support patient care and optimize long-term clinical outcomes. Proper management involves identifying risk factors, establishing staging parameters, and initiating standard-of-care therapies under professional medical supervision.

Key Clinical Metrics & Biomarkers

Detailed Clinical Protocol

1. Vitamin K Forms (K1/Phylloquinone — Plant Sources, Leafy Greens, Dietary Main Form, Half-Life 1-2 Hours; K2/Menaquinones — Bacterial/Fermented, MK-4 (Animal, Rapid Turnover), MK-7 (Natto, Long Half-Life 72 Hours, Most Bioactive); K3/Menadione — Synthetic, Toxic, Not Used in Humans; K2 More Effective for Bone & Cardiovascular)

• Clinical Staging & Risk Stratification: The clinical progression and severity of Vitamin K Forms (K1/Phylloquinone — Plant Sources, Leafy Greens, Dietary Main Form, Half-Life 1-2 Hours; K2/Menaquinones — Bacterial/Fermented, MK-4 (Animal, Rapid Turnover), MK-7 (Natto, Long Half-Life 72 Hours, Most Bioactive); K3/Menadione — Synthetic, Toxic, Not Used in Humans; K2 More Effective for Bone & Cardiovascular) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

2. RDA & Units (RDA — 120 mcg Men, 90 mcg Women; Pregnancy 90 mcg, Lactation 90 mcg; No Established Upper Limit — Very Safe; K2 Not Separately RDA’d; Adequate Intake Based on K1; MK-7 Effective at Much Lower Doses Due to Long Half-Life; 100-200 mcg MK-7 Common Supplement)

• Clinical Staging & Risk Stratification: The clinical progression and severity of RDA & Units (RDA — 120 mcg Men, 90 mcg Women; Pregnancy 90 mcg, Lactation 90 mcg; No Established Upper Limit — Very Safe; K2 Not Separately RDA’d; Adequate Intake Based on K1; MK-7 Effective at Much Lower Doses Due to Long Half-Life; 100-200 mcg MK-7 Common Supplement) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

3. K1 Food Sources (Per 100g: Natto 1,000 mcg (K2 MK-7); Kale 817 mcg; Spinach 483 mcg; Collards 440 mcg; Swiss Chard 830 mcg; Parsley 1,640 mcg; Broccoli 141 mcg; Brussels Sprouts 140 mcg; Romaine 103 mcg; Asparagus 42 mcg; Avocado 21 mcg; K1 Fat-Soluble — Add Fat for Absorption; Cooking Reduces 20-50%)

• Clinical Staging & Risk Stratification: The clinical progression and severity of K1 Food Sources (Per 100g: Natto 1,000 mcg (K2 MK-7); Kale 817 mcg; Spinach 483 mcg; Collards 440 mcg; Swiss Chard 830 mcg; Parsley 1,640 mcg; Broccoli 141 mcg; Brussels Sprouts 140 mcg; Romaine 103 mcg; Asparagus 42 mcg; Avocado 21 mcg; K1 Fat-Soluble — Add Fat for Absorption; Cooking Reduces 20-50%) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

4. K2 Food Sources (MK-4 — Animal: Egg Yolk 32 mcg, Butter 15 mcg, Chicken Liver 13 mcg, Chicken Breast 9 mcg, Beef 3 mcg; MK-7 — Fermented: Natto 1,000 mcg/100g, Hard Cheese 10-50 mcg, Soft Cheese 5-10 mcg, Sauerkraut 5 mcg; MK-7 from Gut Bacteria Synthesis — Limited, Debated Contribution; Fermented Foods Best K2 Source)

• Clinical Staging & Risk Stratification: The clinical progression and severity of K2 Food Sources (MK-4 — Animal: Egg Yolk 32 mcg, Butter 15 mcg, Chicken Liver 13 mcg, Chicken Breast 9 mcg, Beef 3 mcg; MK-7 — Fermented: Natto 1,000 mcg/100g, Hard Cheese 10-50 mcg, Soft Cheese 5-10 mcg, Sauerkraut 5 mcg; MK-7 from Gut Bacteria Synthesis — Limited, Debated Contribution; Fermented Foods Best K2 Source) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

5. Functions — Blood Clotting (Cofactor for Gamma-Glutamyl Carboxylase; Activates Clotting Factors II (Prothrombin), VII, IX, X; Also Proteins C, S, Z (Anticoagulant); Warfarin Blocks Vitamin K Epoxide Reductase — Antagonizes K; Consistent K Intake Critical on Warfarin; Don’t Avoid Greens, Keep Consistent)

• Clinical Staging & Risk Stratification: The clinical progression and severity of Functions — Blood Clotting (Cofactor for Gamma-Glutamyl Carboxylase; Activates Clotting Factors II (Prothrombin), VII, IX, X; Also Proteins C, S, Z (Anticoagulant); Warfarin Blocks Vitamin K Epoxide Reductase — Antagonizes K; Consistent K Intake Critical on Warfarin; Don’t Avoid Greens, Keep Consistent) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

6. Functions — Bone Health (Activates Osteocalcin — Bone Matrix Protein, Binds Calcium to Bone; Matrix Gla Protein (MGP) — Inhibits Vascular Calcification; Undercarboxylated = Inactive = Calcium Goes to Arteries Not Bones; K2 MK-7 Most Effective for Bone; Japan Uses MK-4 45mg Prescription for Osteoporosis)

• Clinical Staging & Risk Stratification: The clinical progression and severity of Functions — Bone Health (Activates Osteocalcin — Bone Matrix Protein, Binds Calcium to Bone; Matrix Gla Protein (MGP) — Inhibits Vascular Calcification; Undercarboxylated = Inactive = Calcium Goes to Arteries Not Bones; K2 MK-7 Most Effective for Bone; Japan Uses MK-4 45mg Prescription for Osteoporosis) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

7. Functions — Cardiovascular (MGP Prevents Arterial Calcification; Rotterdam Study — Highest K2 Intake = 57% Lower Cardiac Death, 52% Lower Severe Aortic Calcification; K2 Directs Calcium to Bones, Away from Arteries; Synergy with Vitamin D (Increases Calcium Absorption) + K2 (Directs It); D+K2+Magnesium Optimal Combo)

• Clinical Staging & Risk Stratification: The clinical progression and severity of Functions — Cardiovascular (MGP Prevents Arterial Calcification; Rotterdam Study — Highest K2 Intake = 57% Lower Cardiac Death, 52% Lower Severe Aortic Calcification; K2 Directs Calcium to Bones, Away from Arteries; Synergy with Vitamin D (Increases Calcium Absorption) + K2 (Directs It); D+K2+Magnesium Optimal Combo) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

8. Drug Interactions & Safety (Warfarin/Coumadin — Vitamin K Antagonist, Consistent Intake Essential, Don’t Eliminate Greens, Monitor INR; Antibiotics — Reduce Gut K2 Synthesis; Bile Acid Sequestrants — Reduce Fat-Soluble Vitamin Absorption; Orlistat — Fat Malabsorption; Very Safe, No Toxicity Known; Newborn Injection Prevents Hemorrhagic Disease)

• Clinical Staging & Risk Stratification: The clinical progression and severity of Drug Interactions & Safety (Warfarin/Coumadin — Vitamin K Antagonist, Consistent Intake Essential, Don’t Eliminate Greens, Monitor INR; Antibiotics — Reduce Gut K2 Synthesis; Bile Acid Sequestrants — Reduce Fat-Soluble Vitamin Absorption; Orlistat — Fat Malabsorption; Very Safe, No Toxicity Known; Newborn Injection Prevents Hemorrhagic Disease) are evaluated dynamically based on standard staging charts, GFR indicators, or organ clearance tables. Proper stratification helps design customized nutritional plans tailored to the patient's exact level of function.
• Pathophysiological Biomarkers & Targets: Essential biomarkers, including serum chemistry levels, blood urea nitrogen (BUN), specific systemic hormones, and inflammatory proteins, are monitored routinely to measure progress and adjust therapeutic dosing schedules under strict clinical supervision.
• Evidence-Graded Therapeutic Guidance: Implementation of clinical nutrition protocols is designed to minimize the metabolic load on clearance organs. Interventions emphasize specific amino acid ratios, mineral restrictions (such as sodium, potassium, and phosphorus), and bioactive antioxidant synergies to support tissue repair and cellular recovery.
• Structured Patient Action Steps: Daily self-management involves tracking fluid intake, monitoring blood pressure trends, optimizing circadian sleep-wake cycles, and scheduling periodic blood chemistry profiles under the supervision of a registered clinical specialist.

Frequently Asked Questions (AEO / Speakable)

Q1: What is the primary clinical objective when managing Vitamin K: K1 Phylloquinone, K2 MK-4 & MK-7, Osteocalcin & the Calcium-Directing Vitamin?

A1: The primary clinical objective is to stabilize baseline organ function, minimize metabolic clearance stress, and implement targeted nutritional swaps that prevent further cellular damage. By aligning daily nutrition with evidence-graded clinical pathways, patients can optimize recovery rates and support long-term organ preservation.

Q2: Which biomarkers are most critical to monitor for Vitamin K: K1 Phylloquinone, K2 MK-4 & MK-7, Osteocalcin & the Calcium-Directing Vitamin?

A2: Clinicians monitor standard laboratory values, functional staging charts, and symptom presentation metrics to guide therapeutic dosing. Staging guidelines (such as GFR levels or specific blood profiles) dictate the level of restriction required for protein, fluid, and trace minerals.

Q3: When should a patient seek immediate specialist consultation?

A3: Patients should seek immediate medical consultation if they experience rapid functional decline, severe symptom exacerbation, or when primary biomarker readings cross the established clinical action thresholds. Adjustments to medical or dietary regimens must be managed under direct supervision.

Evidence-Graded Lifestyle Swaps & Supportive Nutrition

Integrative care plays a supportive role alongside standard pharmacotherapy and surgical interventions. Clinicians and patients should review evidence-graded strategies to reduce metabolic stress, manage systemic loads, and optimize physical function:

1. Precision Nutrition: Implement diet plans tailored to the specific stage of disease, ensuring adequate nutrient density while limiting minerals or fluids that tax organ clearance. Meal timing should align with circadian rhythms to support hormone balance and insulin sensitivity.
2. Avoiding Toxins: Minimize exposure to toxic substances, including non-steroidal anti-inflammatory drugs (NSAIDs), excessive alcohol, and environmental contaminants. Clinicians should review all medications to ensure renal and hepatic safety.
3. Structured Lifestyle Modifications: Coordinate with physical therapists and clinical specialists to design safe, low-impact exercise routines that preserve lean mass and support cardiovascular health. Engaging in structured physical activity helps regulate glycemic indices and cardiovascular tone.

[!IMPORTANT] All diagnostic protocols, treatment pathways, medication dosing adjustments, and nutritional swaps must be conducted under the direct supervision and guidance of a licensed healthcare professional.